Qyuns Therapeutics Snares ￥10M in Series B+ Round - vcbeat
Summary
Previously, Qyuns Therapeutics has completed a 100M Series B financing led by Hongtai Aplus, with participation from Triwise Capital and Hefu Ruitai.Founded in 2015 in China Medical City (Taizhou), Qyuns Therapeutics is a biopharmaceutical company focused on the development of high-quality antibody drugs for the treatment of autoimmune diseases. The company aims to improve patient access to advanced and affordable medicine through science and innovation. The company has a team of highly-skilled talents with extensive experience across drug development, CMC, quality, and compliance.Qyuns Therapeutics has eight programs under research and development, covering indications included psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, asthma, etc. In addition, the company has two biosimilars to enter the phase III clinical trial, and its first innovative drug is about to enter phase II, with a number of pipelines that will enter the clinical stage or complete preclinical development by 2020.Besides, the CDMO platform project jointly built by Qyuns Therapeutics and China Medical City for biological drugs has been fully launched, and 8 production lines will be built in the first phase. The platform is the key project of China Medical City, which can not only prepare for the mass production of Qyuns Therapeutics, but also serve other biopharmaceutical enterprises.Lucky Source Funds is an equity investment firm focuses on biomedical health, with its business covering investment in angel, VC, PE, and industrial mergers and acquisitions.